![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Bladder Cancer |
Free Subscription
1 Am J Ther |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Bladder Cancer is free of charge.
Immunotherapy in Bladder Cancer.
Am J Ther. 2022;29:e334-e337.
PubMed
Abstract available
Metastatic urothelial carcinoma to the colon presenting with pelvic abscess
tracking to the right hip joint.
ANZ J Surg. 2022;92:1229-1231.
PubMed
Appl Immunohistochem Mol Morphol
Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
Appl Immunohistochem Mol Morphol. 2022;30:326-332.
PubMed
Abstract available
TMEM2 expression is downregulated as bladder cancer invades the muscle layer.
Biochem Biophys Res Commun. 2022;613:1-6.
PubMed
Abstract available
CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune
response in bladder cancer.
Biochem Biophys Res Commun. 2022;613:12-18.
PubMed
Abstract available
Biochim Biophys Acta Mol Cell Res
Corrigendum to "lncRNA H19 regulates epithelial-mesenchymal transition and
metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA" [Biochim.
Biophys. Acta Mol. Cell Res. 1864 (2017) 1887-1899/BBAMCR-17-151R2].
Biochim Biophys Acta Mol Cell Res. 2022;1869:119281.
PubMed
Chemical tools to monitor bladder cancer progression.
Biomarkers. 2022 May 9:1-41. doi: 10.1080/1354750X.2022.2076153.
PubMed
Abstract available
A novel and sensitive DNA methylation marker for the urine-based liquid biopsies
to detect bladder cancer.
BMC Cancer. 2022;22:510.
PubMed
Abstract available
Digital image analysis of high-grade urothelial carcinoma in urine cytology
confirms chromasia heterogeneity and reveals a subset with hypochromatic nuclei
and another with extremely dark or "India ink" nuclei.
Cancer Cytopathol. 2022;130:363-369.
PubMed
Abstract available
Optimal first-line treatment for platinum-eligible metastatic urothelial
carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A
systematic review and meta-analysis.
Clin Immunol. 2022;236:108927.
PubMed
Abstract available
NAT10-mediated mRNA N4-acetylcytidine modification promotes bladder cancer
progression.
Clin Transl Med. 2022;12:e738.
PubMed
Abstract available
The Paris system classification for urinary cytology in patients under bacillus
Calmette-Guerin treatment.
Diagn Cytopathol. 2022;50:289-294.
PubMed
Abstract available
Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk
Modification by Common Genetic Polymorphisms in Two Case-Control Studies.
Environ Health Perspect. 2022;130:57006.
PubMed
Abstract available
Compound to Clinic? A Preclinical High-throughput Screening Pathway To Expedite
Drug Discovery in Bladder Cancer.
Eur Urol. 2022 May 5. pii: S0302-2838(22)01811.
PubMed
Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive
and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical
Cystectomy: Results from a Retrospective Multicenter Study.
Eur Urol Open Sci. 2022;39:14-21.
PubMed
Abstract available
A Multicenter Retrospective Cohort Series of Muscle-invasive Bladder Cancer
Patients Treated with Definitive Concurrent Chemoradiotherapy in Daily Practice.
Eur Urol Open Sci. 2022;39:7-13.
PubMed
Abstract available
Classification of retinoblastoma-1 gene mutation with machine learning-based
models in bladder cancer.
Heliyon. 2022;8:e09311.
PubMed
Abstract available
Prediction of the Immune Phenotypes of Bladder Cancer Patients for Precision
Oncology.
IEEE Open J Eng Med Biol. 2022;3:47-57.
PubMed
Abstract available
Response to Letter to the Editor 'Serum irisin concentration in patients with
bladder cancer'.
Int Urol Nephrol. 2022;54:1247-1248.
PubMed
A molecular dynamics and docking study to screen anti-cancer compounds targeting
mutated p53.
J Biomol Struct Dyn. 2022;40:2407-2416.
PubMed
Abstract available
Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology.
J Clin Oncol. 2022;40:1583-1589.
PubMed
Abstract available
NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant
chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
J Immunother Cancer. 2022;10.
PubMed
Abstract available
Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical
Implementation Steps for Infusion Nurses.
J Infus Nurs. 2022;45:142-153.
PubMed
Abstract available
Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for
Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
J Urol. 2022;207:1302-1311.
PubMed
Abstract available
The Development of Non-Invasive Diagnostic Tools in Bladder Cancer.
Onco Targets Ther. 2022;15:497-507.
PubMed
Abstract available
Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based
Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint
Inhibitors for Advanced Urothelial Carcinoma.
Oncologist. 2022;27:e406-e409.
PubMed
Abstract available
circSPECC1 promotes bladder cancer progression via regulating miR-136-5p/GNAS
axis.
Pathol Res Pract. 2022;234:153914.
PubMed
Abstract available
Cytokeratin 5/6 expression in pT1 bladder cancer predicts intravesical recurrence
in patients treated with bacillus Calmette-Guerin instillation.
Pathology. 2022 May 5. pii: S0031-3025(22)00124.
PubMed
Abstract available
A retrospective study on optimal number of cycles of the first-line
platinum-based chemotherapy for metastatic urothelial carcinoma.
Urol Oncol. 2022;40:194.
PubMed
Abstract available
Real-world treatment patterns and clinical outcomes among patients with advanced
urothelial carcinoma in the United States.
Urol Oncol. 2022;40:195.
PubMed
Abstract available
Current practice patterns in the perioperative management of patients undergoing
radical cystectomy: Results from a global survey.
Urol Oncol. 2022;40:196.
PubMed
Abstract available
An evaluation of trends in the representation of patients by age, sex, and
diverse race/ethnic groups in bladder and kidney cancer clinical trials.
Urol Oncol. 2022;40:199.
PubMed
Abstract available
[Extended vs. standard lymphadenectomy for the treatment of urothelial carcinoma
of the bladder in patients undergoing radical cystectomy].
Urologe A. 2022;61:530-533.
PubMed
Can artificial intelligence help reduce unnecessary bladder biopsies? Comment on
"Assessing treatment response after intravesical bacillus Calmette-Guerin
induction cycle: are routine bladder biopsies necessary".
World J Urol. 2022;40:1241-1242.
PubMed
Explainable artificial intelligence (XAI): closing the gap between image analysis
and navigation in complex invasive diagnostic procedures.
World J Urol. 2022;40:1125-1134.
PubMed
Abstract available
Comment on "Durability of response to primary chemoablation of low-grade upper
tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal
gel: OLYMPUS trial final report".
World J Urol. 2022;40:1251-1252.
PubMed
Zhong Nan Da Xue Xue Bao Yi Xue Ban
MiR-133b regulates the proliferation, colony formation, and invasion of bladder
cancer cells via inhibiting SOX4.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022;47:407-415.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by